These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [The clinical significance of serum tissue polypeptide antigen as a tumor marker for urogenital carcinomas--a comparison with other tumor markers in patients with renal cell carcinoma and prostatic carcinoma].
    Author: Yamazaki K, Kumamoto Y, Tsukamoto T, Umehara T, Ohmura K.
    Journal: Hinyokika Kiyo; 1987 Oct; 33(10):1581-9. PubMed ID: 2451408.
    Abstract:
    Serum tissue polypeptide antigen (s-TPA) levels were determined in 124 patients having urogenital carcinomas, 74 with benign urological diseases and 55 normal subjects. We analyzed these results and determined the clinical significance of s-TPA as a tumor marker for urogenital carcinomas. S-TPA levels in the 55 normal subjects was 80 +/- 17 U/L (mean +/- S.D.). Since more than 95% of them showed an s-TPA level of below 110 U/L, this level was used as the cut-off value. The s-TPA level was 125 +/- 75 U/L for the 42 patients with benign prostatic hypertrophy, 138 +/- 60 U/L for the 15 patients with acute urinary tract infections (UTI) and 80 +/- 20 U/L in the 17 patients having other benign urological diseases. An elevated s-TPA level was clearly demonstrated in the case of acute UTI, which displayed a false positive result. The s-TPA level was 207 +/- 246 U/L for the 21 patients with bladder carcinoma, 197 +/- 52 U/L for the 5 patients with renal pelvic or ureteral carcinoma, 187 +/- 156 U/L for the 22 patients with renal cell carcinoma, 167 +/- 183 U/L for the 46 patients with prostatic carcinoma, and 95 +/- 28 U/L for the 8 patients with testicular carcinoma. In the 8 patients having bladder carcinoma, the elevation of s-TPA level seemed to be caused by the concomitant presence of acute UTI. The positive rate of s-TPA in various urogenital carcinomas was 100% for renal pelvic or ureteral carcinoma, 68% for renal cell carcinoma, 59% for bladder carcinoma, 52% for prostatic carcinoma and 13% for testicular carcinoma.(ABSTRACT TRUNCATED AT 250 WORDS)
    [Abstract] [Full Text] [Related] [New Search]